Latest News for: 003

Edit

ISCAP Appeal 2012-003 (NARA - National Archives and Records Administration)

Public Technologies 24 Apr 2026
) On March 16th, 2026, the ISCAP released a 13-page document from the Central Intelligence Agency (CIA) ... This is an abstract of the document ... Attachments Original document Permalink. Disclaimer ... (noodl.
Edit

Request for tender - RFT26-003 Wadandi Track Construction (City of Busselton)

Public Technologies 24 Apr 2026
) Request for tender - RFT26-003 Wadandi Track Construction. Published on Friday, 24 April 2026 at 1.12.06 PM ... All tender submissions must be received by 2.00pm (AWST) on Friday 22 May 2026 ... Giving Statewide public notice of the invitation to tender.
Edit

Ba 2025-02-14 UB UT OAG-003-25 Cover Letter Petition UB (The eRulemaking Program)

Public Technologies 23 Apr 2026
). OFFICE OF THE ATTORNEY GENERAL. STATE OF UTAH. DEREK E. BROWN. ATTORNEY GENERAL. Mark E. Burns. Daniel Burton. Douglas Crapo. Standford E. Purser. Stewart M. Young. Civil Deputy Attorney General. Chief Deputy Attorney General & General Counsel ... OAG-003-25 ... Re.
Edit

Tender RFT 26-003 Wadandi Track Construction (Shire of Augusta-Margaret River)

Public Technologies 22 Apr 2026
) Construction of Wadandi Track Tender. The Shire of Augusta Margaret River is seeking tenders from appropriate parties for the construction of Sections 8-11 of the Wadandi Track ... Tender RFT 26-003 WADANDI TRACK CONSTRUCTION, SECTIONS 8-11 & 20-22.
Edit

BPL-003 Sales Forecast to 2034 Signals Transformational Growth in Treatment-Resistant Depression Market Driven by Rapid-Acting ...

GetNews 22 Apr 2026
"BPL-003 Sales Forecast" ... DelveInsight’s comprehensive analysis of BPL-003 sales, BPL-003 sales forecast, BPL-003 cost, and BPL-003 price trends provides valuable insights for stakeholders looking to capitalize on this high-growth opportunity.
Edit

Drug Farm to Present Positive Phase 1b Data for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™

Pharmiweb 17 Apr 2026
In this multicenter, open-label Phase 1b study (NCT06395285), six adult patients with genetically confirmed ROSAH syndrome associated with the ALPK1 T237M mutation received once-daily oral DF-003 treatment for four weeks ... About DF-003.
Edit

66415 003 BMK WEB (Brighthouse Financial Inc)

Public Technologies 16 Apr 2026
). Notice of 2026 Annual Meeting and Proxy Statement. We're Brighthouse Financial. We are on a mission to help people achieve financial security. As one of the largest providers of annuities and life insurance in the U.S.,1 ... Best's Review®. Top 200 U.S ... 69.
Edit

AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant

Hastings Tribune 08 Apr 2026
66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohortsDurable responses observed at Day 85. 83% (5/6) (10 mg) and 66.7% (4/6) ... .
Edit

AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a ...

Nasdaq Globe Newswire 08 Apr 2026
BPL-003 was generally well tolerated with no serious adverse events reported, and participants achieved a mean discharge approximately 100 minutes post-dose.
Edit

AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs (Atai Beckley Inc)

Public Technologies 08 Apr 2026
) 66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohorts Durable responses observed at Day 85 ... About BPL-003.
×